BioTuesdays

Category - Markets

Satsuma Pharmaceuticals
Markets

SVB Leerink starts Satsuma Pharma at OP; PT $20

SVB Leerink launched coverage of Satsuma Pharmaceuticals (NASDAQ:STSA) with an “outperform” rating and $20 price target. The stock closed at $10.70 on Oct. 7. STS101, Satsuma’s lead asset, is a dry-powder formulation of...

October 8, 2019
Sutra-Biopharma-Logo
Markets

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...

October 7, 2019
Markets

SVB Leerink ups AMAG Pharma PT to $14 from $9

SVB Leerink raised its price target for AMAG Pharmaceuticals (NASDAQ:AMAG) to $14 from $9 ahead of an FDA advisory committee meeting on Oct. 29. The stock closed at $11.50 on Oct. 4. “Based on our MEDACorp survey of 50...

October 7, 2019
Fulcrum Therapeutics
Markets

HCW starts Fulcrum Therapeutics at buy; PT $21

H.C. Wainwright launched coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a “buy” rating and $21 price target. The stock closed at $6.59 on Oct. 2. Fulcrum’s lead program, losmapimod, a p38 alpha/beta MAP kinase...

October 3, 2019
PhaseBio Pharmaceuticals
Markets

HCW starts PhaseBio Pharma at buy; PT $18

H.C. Wainwright initiated coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a “buy” rating and $18 price target. The stock closed at $4.03 on Oct. 2. PhaseBio’s Phase 2 candidate, PB2452, which is licensed from...

October 3, 2019
Fate Therapeutics
Markets

Stifel starts Fate Therapeutics at buy; PT $27

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...

September 30, 2019
Daxor
Markets

Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

September 30, 2019
Concert Pharma
Markets

Stifel cuts Concert Pharma to hold; PT to $8 from $18

Stifel downgraded Concert Pharmaceuticals (NASDAQ:CNCE) to “hold” from “buy” and lowered its price target to $8 from $18 after the company reported a Phase 3 trial failure with its AVP-786 drug candidate in Alzheimer’s...

September 27, 2019
Hookipa Pharma Logo
Markets

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...

September 27, 2019